Please complete Pre-test

Chapter 1 of 4

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, participants will learn about key highlights of the latest and most impactful data in acute myeloid leukemia (AML), presented at the 2017 European Hematology Association (EHA) 22nd Congress.

Chapter 1: Combination Therapy with Novel Agents and Chemotherapy Improves Survival in Diverse Subsets of AML Patients

Chapter 2: Safety and Efficacy of Enasidenib in Patients with Mutant-IDH2 Relapsed AML

Chapter 3: Improving Efficacy of Mutation-specific Therapeutic Options in AML: Emerging Data and Novel Agents

Chapter 4: Improved Efficacy, Safety with CPX-351 in Older Adults with Newly Diagnosed Therapy Related AML

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating emerging and targeted therapies and treatment strategies in patients with acute myeloid leukemia (AML)
  • Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in AML

Agenda

Chapter 1: Combination Therapy with Novel Agents and Chemotherapy Improves Survival in Diverse Subsets of AML Patients

  • Nivolumab-AZA Combination Therapy Improves Stable Disease in Relapsed AML (S474) – Naval Daver, MD
  • Outpatient Azacitidine-based Chemotherapy Combined with BCL-2 Suppressing Agent Induces Durable Deep Remissions in AML (S472) – Keith W. Pratz, MD

Chapter 2: Safety and Efficacy of Enasidenib in Patients with Mutant-IDH2 Relapsed AML

  • Enasidenib Improved Durable Remissions in Patients with Mutant-IDH2 Relapsed AML (S471) – Eytan M. Stein, MD
  • Neither Complex Karyotype nor FLT3/ITD Predicts for Worsened Outcomes in Patients with AML Receiving 7+3 (P553) – Eytan M. Stein, MD
  • Monitoring for and Managing Differentiation Syndrome in AML Patients Prescribed Enasidenib (P215) – Eytan M. Stein, MD

Chapter 3: Improving Efficacy of Mutation-specific Therapeutic Options in AML: Emerging Data and Novel Agents

  • The Pan-FLT3 Inhibitor Crenolanib is Effective Against Multiple FLT3 Mutations (P552) – Richard M. Stone, MD
  • Potency of Quizartinib in Patients with Relapsed Mutant FLT3-ITD AML (S475) – Richard M. Stone, MD
  • Mutational Status Correlates with Response to Pracinostat in Older AML Patients (P207) – Ehab Atallah, MD

Chapter 4: Improved Efficacy, Safety with CPX-351 in Older Adults with Newly Diagnosed Therapy Related AML

  • Overall Survival with CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, Therapy-related Acute Myeloid Leukemia (P556) – Jorge E. Cortes, MD

Instructions for Participation and Credit

This activity is eligible for credit through July 21, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Ehab Atallah, MD
Associate Professor of Medicine
Medical College of Wisconsin
Division of Hematology and Oncology
Milwaukee, Wisconsin

Dr. Ehab Atallah received his medical degree from Cairo University School of Medicine. He completed an internal medicine residency in the Cleveland Clinic Health System, a fellowship in hematology/oncology at the Karmanos Cancer Center, where he served as chief fellow, as well as a leukemia fellowship at MD Anderson Cancer Center. Dr. Atallah is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in leukemia and myelodysplastic syndromes at Froedtert Hospital.

Dr. Atallah is board certified in internal medicine, medical oncology, and hematology. He has authored numerous publications, including journal articles and meeting abstracts. His current research interests include the treatment of patients with chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myelogenous leukemia, myeloproliferative neoplasms, and myelodysplastic syndromes.

Jorge E. Cortes, MD
Deputy Chair and Chair
Chronic and Acute Myelogenous Leukemia Sections
Department of Leukemia
The University of Texas, MD Anderson Cancer Center
Houston, Texas

Dr. Jorge Cortes received his medical degree from Facultad de Medicina, Universidad Nacional Autónoma de Mexico in Mexico City, and additional hematology/oncology training at The University of Texas, MD Anderson Cancer Center. He is the Deputy Chair and Chair of the Chronic and Acute Myelogenous Leukemia sections in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.

Dr. Cortes is a worldwide expert in leukemia research, with a unique expertise in clinical and translational research in leukemia, particularly myeloid leukemias. He is program director of the Leukemia Fellowship Program, a unique program that he initiated in 2000, and he has mentored more than 25 clinical fellows. Dr. Cortes has authored more than 800 manuscripts in peer-reviewed journals and is the principal investigator (PI) or co-PI of more than 45 research studies. He has worked on development and approval of new leukemia drugs such as bosutinib, ponatinib and omacetaxine, and others that have completed or are close to completing pivotal trials, such as CPX-351, Quizartinib and crenolanib. Dr. Cortes has been recognized with numerous awards for his contributions in the field.

Naval Daver, MD
Assistant Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Naval Daver received his medical degree from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine in Houston, Texas. He is an Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

A clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myelofibrosis, Dr. Daver is the co/principal investigator for more than 25 ongoing clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing immune checkpoint- and vaccine-based approaches in AML, myelodysplastic syndromes (MDS), and myelofibrosis, and is conducting a number of these trials. Dr. Daver has published more than 100 peer-reviewed manuscripts. He has also authored numerous abstracts at national and international conferences.

Keith W. Pratz, MD
Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Dr. Keith Pratz received his medical degree from UMDNJ Robert Wood Johnson Medical School, Camden, New Jersey. He completed his residency in internal medicine at Mayo Graduate School of Medicine, Rochester, Minnesota, and his fellowship in medical oncology at The Johns Hopkins Hospital, Baltimore, Maryland. Dr. Pratz is a clinical investigator of novel therapeutics for acute leukemias and is an Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is the principal investigator on clinical trials incorporating novel targeted therapies into combination chemotherapy in acute leukemia. Dr. Pratz is also active in designing, coordinating, and conducting laboratory correlative studies in the setting of investigational therapies to aid in the development of improved treatments for hematologic malignancies.

Eytan M. Stein, MD
Assistant Professor
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. He is an Assistant Professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Stein holds board certification from the American Board of Internal Medicine, American Board of Clinical Oncology, and the American Board of Hematology. He focuses his practice on the treatment of acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. His research interests include developing novel, early phase clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies.

Richard Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director, Adult Acute Leukemia Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Richard Stone received his medical degree from Harvard Medical School, Boston. He completed his internal medicine residency training at Brigham and Women’s Hospital and his hematology-oncology fellowship at Dana-Farber Cancer Institute. He is the Chief of Staff and Director of the Adult Acute Leukemia Program at Dana-Farber, and Professor of Medicine at Harvard Medical School. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies including acute leukemia, myeloproliferative disorders, and myelodysplastic syndrome (a bone marrow failure state that may convert to leukemia).

In addition to his work at Dana-Farber, Dr. Stone serves as Chair of the Medical Oncology Board of the American Board of Internal Medicine, Chair of the Medical Advisory Board of the Aplastic Anemia & MDS International Foundation, and Chairman of the Leukemia Core Committee for the National Cooperative Trials Group the Alliance.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-17-160-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 17-160-060

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Ehab Atallah has disclosed no relevant financial relationships.

Dr. Jorge Cortes has received honoraria as a consultant and grant support related to research activities from Astellas Pharma US, Inc., Novartis AG, and Pfizer Inc., Inc., in addition to grant support related to research activities from Arog Pharmaceuticals, Inc. and ImmunoGen, Inc.

Dr. Naval Daver has received honoraria related to formal advisory activities from Incyte Corporation, Karyopharm Therapeutics, and Otsuka Pharmaceutical Co., Ltd.; as well as consultant fees from ImmunoGen, Inc., Incyte, Pfizer Inc., Jazz Pharmaceuticals plc, Novartis AG, and Sunesis Pharmaceuticals, Inc. He has received grant support related to research activities from Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Incyte, Karyopharm, Pfizer, and Sunesis.

Dr. Keith Pratz has received grant support related to research activities from AbbVie Inc., Agios, Astellas Pharma US, Inc., and Millennium Pharmaceuticals, Inc.

Dr. Eytan Stein has received honoraria related to formal advisory activities from Agios and Celgene Corporation.

Dr. Richard Stone has received honoraria as a consultant from AbbVie Inc., Agios, Amgen Inc., Arog Pharmaceuticals, Inc., Astellas Pharma US, Inc., Celgene Corporation, Fujifilm Corporation, Jazz Pharmaceuticals plc, Novartis AG, Ono Pharmaceutical Co., Ltd., Orsenix Holdings BV, Pfizer Inc., and Sumitomo Dainippon Pharma Co., Ltd. He has also disclosed a financial relationship with the data safety monitoring board (DSMB): Celgene.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.